secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2026-06-04T21:00:25+00:00
Accession:  0001193125-26-257684
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Therapeutics CFO resigns, appoints new CFO and two independent directors
--------------------------------------------------------------------------------

- CFO Nicholas Maestas resigns effective June 5, 2026; Justin Trojanowski named VP Finance, Principal Financial Officer and Corporate Secretary.
- Board appoints Drake Richey and John Yee, MD, MPH as Class II independent directors effective June 4, 2026.
- Company received Nasdaq non-compliance notice on May 22 due to board vacancies; believes it can cure with one remaining vacancy.
- Amended director compensation policy reduces annual cash retainers: base $20K, committee chair $5K-$10K, member $2.5K-$5K.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/0001193125-26-257684-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000119312526257684/d91703d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257684

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer